Prolyl oligopeptidase and dipeptidyl peptidase II/dipeptidyl peptidase IV ratio in the cerebrospinal fluid in Parkinson’s disease: historical overview and future prospects-Reference-Cited by-同舟云学术

Prolyl oligopeptidase and dipeptidyl peptidase II/dipeptidyl peptidase IV ratio in the cerebrospinal fluid in Parkinson’s disease: historical overview and future prospects

Published:2016-08-08 Issue:6 Volume:124 Page:739-744
ISSN:0300-9564
Container-title:Journal of Neural Transmission
language:en
Short-container-title:J Neural Transm

Author:

Nagatsu Toshiharu

Publisher

Springer Science and Business Media LLC

Subject

Biological Psychiatry,Psychiatry and Mental health,Neurology (clinical),Neurology

Link

http://link.springer.com/article/10.1007/s00702-016-1604-8/fulltext.html

Reference49 articles.

1. Abbott CA, Baker E, Sutherland GR, McCaughan GW (1994) Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene. Immunogenetics 40:331–338

2. Agirregoitia N, Casis L, Gil J, Ruiz F, Irazusta J (2007) Ontogeny of prolyl endopeptidase and pyroglutamyl peptidase in rat tissues. Regul Pept 139:52–58

3. Barrett AJ, Rawlings ND (1992) Oligopeptidases, and the emergence of the prolyl endopeptidase family. Biol Chem Hoppe-Seyler 373:353–360

4. Brandt I, Gerard M, Sergeant K, Devreese B, Baekelandt V, Augustyns K, Scharpe S, Engelborghs Y, Lambeir AM (2008) Prolyl oligopeptidase stimulates the aggregation of alpha-synuclein. Peptides 29:1472–1478

5. Breen G, Harwood AJ, Gregory K, Sinclair M, Collier D, St Clair D, Williams RS (2004) Two peptidase activities decrease in treated bipolar disorder not schizophrenic patients. Bipolar Disord 6:156–161

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Activity-based NIR specific fluorescent probe reveals the abnormal elevation of prolyl endopeptidase in hippocampus during Alzheimer's disease progression;Sensors and Actuators B: Chemical;2024-10

2. Prolyl oligopeptidase activity (POP) in early stage and medicated schizophrenia and in an animal model for schizophrenia study: In vivo effects of psychopharmacological substances on enzyme activity;Brain Disorders;2023-06

3. Tunable Surface Charge Enables the Electrostatic Adsorption-Controlled Release of Neuroprotective Peptides from a Hydrogel–Nanoparticle Drug Delivery System;ACS Applied Materials & Interfaces;2022-12-15

4. DPP3: From biomarker to therapeutic target of cardiovascular diseases;Frontiers in Cardiovascular Medicine;2022-10-12

5. The many facets of CD26/dipeptidyl peptidase 4 and its inhibitors in disorders of the CNS – a critical overview;Reviews in the Neurosciences;2022-07-01